Decoy Therapeutics Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Decoy Therapeutics Inc. (DCOY) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $0.00 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-03-31
- Decoy Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2019-03-31 was $4.41, a 70.66% decline year-over-year.
- Decoy Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2018-03-31 was $15.03.
- Decoy Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $0.00.
- Decoy Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $0.00.
- Decoy Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $0.00.
- Decoy Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2021 was $0.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2026-03-31 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-21 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-22 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-27 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-25 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-18 | |||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $4.41 10-Q · filed 2019-07-17 | |||
| 2019-03-31 | $4.41 10-Q · filed 2019-05-01 | |||
| 2018-12-31 | $8.19 10-K · filed 2019-03-06 | |||
| 2018-09-30 | $8.35 10-Q · filed 2018-11-05 | |||
| 2018-06-30 | $9.82 10-Q · filed 2018-08-01 | |||
| 2018-03-31 | $15.03 10-Q · filed 2018-05-02 | |||
| 2017-12-31 | $10.51 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |